Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2017-02-769208 http://scihub22266oqcxt.onion/10.1182/blood-2017-02-769208 C5482103!5482103 !28408462     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28408462 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Blood 2017 ; 129 (25 ): 3322-3331 Nephropedia Template TP {{tp|p=28408462 |t=2017. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults |pdf=|usr=}}{{28408462 }} gab.com Text Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=28408462 #FOAvip Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity resulting from transduction of undefined T-cell mixtures, variability of transgene expression, and terminal differentiation of cells at the end of culture. A phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation. Products meeting all defined specifications occurred in 93% of enrolled patients. The maximum tolerated dose was 10(6) CAR T cells per kg, and there were no deaths or instances of cerebral edema attributable to product toxicity. The overall intent-to-treat minimal residual disease-negative (MRD(-)) remission rate for this phase 1 study was 89%. The MRD(-) remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. Twenty-three percent of patients developed reversible severe cytokine release syndrome and/or reversible severe neurotoxicity. These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis. This trial was registered at www.clinicaltrials.gov as #NCT02028455. Twit Text FOAVip Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=28408462 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28408462 #FOAvip English Wikipedia <ref>{{Cite pmid|28408462 }}</ref> Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults #MMPMID28408462 Gardner RA ; Finney O ; Annesley C ; Brakke H ; Summers C ; Leger K ; Bleakley M ; Brown C ; Mgebroff S ; Kelly-Spratt KS ; Hoglund V ; Lindgren C ; Oron AP ; Li D ; Riddell SR ; Park JR ; Jensen MC Blood 2017[Jun]; 129 (25 ): 3322-3331 PMID28408462 show ga Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity resulting from transduction of undefined T-cell mixtures, variability of transgene expression, and terminal differentiation of cells at the end of culture. A phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation. Products meeting all defined specifications occurred in 93% of enrolled patients. The maximum tolerated dose was 10(6) CAR T cells per kg, and there were no deaths or instances of cerebral edema attributable to product toxicity. The overall intent-to-treat minimal residual disease-negative (MRD(-)) remission rate for this phase 1 study was 89%. The MRD(-) remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. Twenty-three percent of patients developed reversible severe cytokine release syndrome and/or reversible severe neurotoxicity. These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis. This trial was registered at www.clinicaltrials.gov as #NCT02028455. |Adolescent [MESH] |Adult [MESH] |Antigens, CD19/*immunology [MESH] |CD4-Positive T-Lymphocytes/immunology/*transplantation [MESH] |CD8-Positive T-Lymphocytes/immunology/*transplantation [MESH] |Child [MESH] |Child, Preschool [MESH] |Female [MESH] |Humans [MESH] |Infant [MESH] |Male [MESH] |Neoplasm Recurrence, Local/immunology/*therapy [MESH] |Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology/*therapy [MESH] |Receptors, Antigen, T-Cell/*immunology [MESH] |Remission Induction [MESH]Intent-to-treat leukemia remission by CD19 CAR T cells of defined form(epmc).pdf DeepDyve Pubget Overpricing